References
- VestboJHurdSSAgustíAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
- QaseemAWiltTJWeinbergerSEDiagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory SocietyAnn Intern Med2011155317919121810710
- O’ReillyJJonesMMParnhamJLovibondKRudolfMManagement of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidanceBMJ2010340c313420581031
- SimpsonCRHippisley-CoxJSheikhATrends in the epidemiology of chronic obstructive pulmonary disease in England: a national study of 51,804 patientsBr J Gen Pract20106057627728420594429
- National Institute for Health and Care ExcellenceChronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care2010 Available from: http://www.nice.org.uk/nicemedia/live/13029/49425/49425.pdfAccessed October 18, 2013
- FeldmanGJImproving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterolInt J Chron Obstruct Pulmon Dis20138899623431038
- FeldmanGSilerTPrasadNEfficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week studyBMC Pulm Med2010101120211002
- JonesPWBarnesNVogelmeierCLawrenceDKramerBEfficacy of indacaterol in the treatment of patients with COPDPrim Care Resp J2011204380388
- DonohueJFFogartyCLotvallJOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178
- KornmannODahlRCentanniSOnce-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J201137227327920693243
- DonohueJFSinghDKornmannOLawrenceDLassenCKramerBSafety of indacaterol in the treatment of patients with COPDInt J Chron Obstruct Pulmon Dis2011647749222003293
- RodrigoGJNeffenHComparison of indacaterol with tiotropium or twice-daily long-acting beta-agonists for stable COPD: a systematic reviewChest201214251104111022383666
- BurgeSWedzichaJACOPD exacerbations: definitions and classificationsEur Respir J Suppl20034146s53s12795331
- ChapmanKRRennardSIDograAOwenRLassenCKramerBLong-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled studyChest20111401687521349928
- DahlRChungKFBuhlREfficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax201065647347920522841
- MrozRMMinarowskiLChyczewskaEIndacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patientsAdv Exp Med Biol2013756232822836615
- MahlerDAD’UrzoABatemanEDConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparisonThorax201267978178822544891
- van NoordJABuhlRLaforceCQVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax201065121086109120978028
- BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J Epub5302013 Available from doi: 10.1183109031936.00200212
- VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804